Table 3.
Summary of the RNA-seq outcomes of 15 separately pooled samples
| Samples | Total reads | Mapped reads | Uniq mapped reads | Multiple mapped reads | GC content(%) | Q30(%) |
|---|---|---|---|---|---|---|
| H1–10 | 28.874 | 26.955 (93.35%) | 23.163 (80.22%) | 3.792 (13.13%) | 44.92 | 89.56 |
| H1–15 | 46.506 | 43.543 (93.63%) | 35.628 (76.61%) | 7.914 (17.02%) | 45.01 | 89.88 |
| H1–20 | 58.818 | 54.118 (92.01%) | 46.657 (79.33%) | 7.460 (12.68%) | 45.32 | 89.59 |
| H1–25 | 74.935 | 69.157 (92.29%) | 60.808 (81.15%) | 8.349 (11.14%) | 44.83 | 90.04 |
| H1–28 | 45.842 | 42.186 (92.02%) | 37.261 (81.28%) | 4.924 (10.74%) | 44.87 | 91.56 |
| H2–10 | 41.384 | 39.026 (94.30%) | 32.371 (78.22%) | 6.656 (16.08%) | 45.16 | 90.86 |
| H2–15 | 51.063 | 47.661 (93.34%) | 38.451 (75.30%) | 9.210 (18.04%) | 44.98 | 89.02 |
| H2–20 | 47.327 | 44.331 (93.67%) | 37.008 (78.20%) | 7.323 (15.47%) | 45.54 | 90.28 |
| H2–25 | 46.285 | 43.048 (93.01%) | 36.495 (78.85%) | 6.553 (14.16%) | 45.03 | 90.69 |
| H2–28 | 46.911 | 43.217 (92.12%) | 36.480 (77.76%) | 6.737 (14.36%) | 44.79 | 90.31 |
| Z36–10 | 32.345 | 30.236 (93.48%) | 25.116 (77.65%) | 5.121 (15.83%) | 44.79 | 89.64 |
| Z36–15 | 41.266 | 38.850 (94.14%) | 31.683 (76.78%) | 7.167 (17.37%) | 44.97 | 90.95 |
| Z36–20 | 47.377 | 43.552 (91.93%) | 36.464 (76.97%) | 7.087 (14.96%) | 45.26 | 90.27 |
| Z36–25 | 47.471 | 43.736 (92.13%) | 38.161 (80.39%) | 5.575 (11.74%) | 45.28 | 90.66 |
| Z36–28 | 49.029 | 45.590 (92.99%) | 33.337 (67.99%) | 12.253 (24.99%) | 46.20 | 90.55 |
H1, H2 and Z36 represent MBI 9915, MBI 9749 and CCRI36, respectively. 10 means 10 day post anthesis (DPA), 15 = 15 DPA, 20 = 20 DPA, 25 = 25 DPA and 28 = 28 DPA